KB-1659

Opucolimab

60287

Background of Opucolimab

Programmed Death Ligand-1 (PD-L1) and Programmed Death Ligand-2 (PD-L2) are expressed on antigen-presenting cells as well as many human cancers and have been shown to downregulate T cell activation and cytokine secretion upon binding to PD-1. Opucolimab can enhance the secretion of IL-2 and IFNγ by T cells and proliferation of CD4+ and CD8+ T cells. Opucolimab exhibits enhanced efficacy and/or anti-tumor activities as compared to certain anti-PD-L1 reference monoclonal antibodies used to treat cancer.

Specifications

Catalog Number	KB-1659
Antibody Name	Opucolimab
Isotype	Human IgG1,lambda
FC Muations	N297A
Target	PDL1
Species Reactivity	Human
Host Cell Line	EXPI CHO
Purification Method	Affinity purified
Concentration	>2 mg/mL
Formulation	50 mM sodium citrate,150mM NaCl,pH5.5
Purity	>95% by SDS-PAGE and SEC-HPLC
Validation	ELISA
Endotoxin Level	<0.2 EU/mg as determined by the LAL method
Sterility	0.2μm filtered
Storage	It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability	Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

US20190225691 - Anti-PD-L1 antibodies and variants